Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 4/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320832 | 0.79 | GABRG2 (0.45) | ULK1MAPK13MAPK12MAPK14 | |
| SCHEMBL320741 | 0.70 | PDGFRB (0.62) | PIK3CAPIK3CDPIK3CBPIK3CGCYP19A1 | |
| SCHEMBL28242154 | 0.66 | PIK3CA (0.47) | S1PR1S1PR3PIK3CAIDO1PIK3CD | |
| SCHEMBL320312 | 0.65 | CYP2A6 (0.50) | S1PR1S1PR3IDO1CYP19A1AAK1 | |
| SCHEMBL1773112 | 0.65 | KDM4E (0.36) | ULK1 | |
| SCHEMBL320478 | 0.65 | DYRK1A (0.40) | PDGFRBPDGFRA | |
| SCHEMBL4027001 | 0.64 | IDO1 (0.55) | S1PR1S1PR3IDO1CYP19A1 | |
| SCHEMBL4753951 | 0.64 | IDO1 (0.49) | IDO1CYP19A1 | |
| SCHEMBL857442 | 0.63 | DAO (0.49) | — | |
| SCHEMBL30165675 | 0.63 | DAO (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018167147-A1 | AZAINDOLES AS INHIBITORS OF HPK1 | F. HOFFMANN-LA ROCHE AG (CH) | 2018-09-20 | — | — | WO | claimed |
| US-11944606-B2 | Azaindoles as inhibitors of HPK1 | GENENTECH, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3596075-B1 | AZAINDOLES AS INHIBITORS OF HPK1 | HOFFMANN LA ROCHE (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-20210299110-A1 | AZAINDOLES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-10952995-B2 | Azaindoles as inhibitors of HPK1 | GENENTECH, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-9051307-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051307-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051307-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| EP-2590946-B1 | Bipyridyl derivatives useful for the treatment of kinase-induced diseases | MERCK PATENT GMBH (DE) | 2015-02-18 | — | — | EP | disclosed |
| EP-2590946-B1 | Bipyridyl derivatives useful for the treatment of kinase-induced diseases | MERCK PATENT GMBH (DE) | 2015-02-18 | — | — | EP | disclosed |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8846931-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846931-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846931-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| EP-2590946-A1 | BIPYRIDYL DERIVATIVES USEFUL FOR THE TREATMENT OF KINASE - INDUCED DISEASES | Merck Patent GmbH (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2012003912-A1 | BIPYRIDYL DERIVATIVES USEFUL FOR THE TREATMENT OF KINASE - INDUCED DISEASES | MERCK PATENT GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012003912-A1 | BIPYRIDYL DERIVATIVES USEFUL FOR THE TREATMENT OF KINASE - INDUCED DISEASES | MERCK PATENT GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | TGFBR1, TGFBR2, SMAD2 | ULK1 430/4885S1PR1 1569/4885S1PR3 1722/4885 |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | TGFBR1, TGFBR2, SMAD2 | ULK1 430/4885S1PR1 1569/4885S1PR3 1722/4885 |
| US-10952995-B2 | Azaindoles as inhibitors of HPK1 | HIPK1, HIPK2, PPIP5K2 | ULK1 5/4885S1PR1 2514/4885S1PR3 2533/4885 |
| US-11944606-B2 | Azaindoles as inhibitors of HPK1 | HIPK1, HIPK2, PPIP5K2 | ULK1 5/4885S1PR1 2514/4885S1PR3 2533/4885 |
| US-20210299110-A1 | AZAINDOLES AS INHIBITORS OF HPK1 | HIPK1, HIPK2, PPIP5K2 | ULK1 5/4885S1PR1 2514/4885S1PR3 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.